Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD The Liver Meeting^® 2025 

– First preclinical data from Controlled Metabolic Accelerator (CMA) pipeline to be presented at ObesityWeek^®

CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., October 14, 2025 – Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating obesity and the resulting cardiometabolic diseases, today announced that clinical data from the company’s Phase 2a M-ACCEL trial evaluating HU6 in patients with MASH (metabolic dysfunction-associated steatohepatitis) will be presented as a late-breaker oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting^® being held November 7-11, 2025 in Washington, DC. The data being presented at AASLD follows positive, topline results disclosed by Rivus in June 2025.

In addition, the company will present the first preclinical data in obesity from its pipeline of oral Controlled Metabolic Accelerators (CMAs) at ObesityWeek^® organized by The Obesity Society (TOS) being held November 4-7, 2025 in Atlanta, GA.  

Presentation details are as follows:

AASLD The Liver Meeting^®, November 7-11, 2025 in Washington, DC. 
Abstract Title: HU6 Oral Investigational Therapy Reduces Liver Fat and Improves Adiposity Markers in Adults with MASH: Top-Line Results from a Phase 2 Randomized Placebo-Controlled Trial (M-ACCEL)
Late-Breaking Abstract Number: 5005
Format: Oral Presentation
Presenter: Mazen Noureddin, M.D., Professor of Medicine at Houston Methodist Hospital and Co-Chairman of the Board of the Summit and Pinnacle Clinical Research Networks
Presentation Date and Time: Monday, November 10, 2025, 2:00 – 2:15 p.m. ET

Late-breaking abstracts will be available on the first day of The Liver Meeting 2025 on Friday, November 7, 2025 at 8:00 am ET.

Obesity Week^®, November 4-7, 2025 in Atlanta, GA
Abstract Title: Oral Controlled-Metabolic Accelerator Drives Fat-Specific Weight Loss and Augments GLP-1 Effect
Abstract Number: 121
Format: Poster Presentation
Presenter: Sol Collado, Ph.D., Senior Director, Drug Discovery, Rivus Pharmaceuticals
Presentation Date and Time: Tuesday, November 4, 2025, 7:30 – 8:30 p.m. ET

A copy of the presentation and poster will be accessible following the presentations under “Clinical Data and Scientific Publications” in Our Science section of Rivus’ website.

About the Phase 2a M-ACCEL Trial

The randomized, double-blind, placebo-controlled, parallel-group Phase 2a M-ACCEL trial (ClinicalTrials.gov: (NCT05979779) evaluated HU6 at 150 mg, 300 mg, and 450 mg once daily for 26 weeks in adults with MASH. Participants were randomized 2:1:2:2 (placebo:HU6 150:HU6 300:HU6 450). Eligible patients had liver fat ≥8% by MRI-PDFF and a VCTE score of 7–15 kPa, targeting fibrosis stages F2-F3. The primary endpoint was percent change from baseline in liver fat as measured by MRI-PDFF at six months. Secondary and exploratory endpoints included proportion of patients achieving ≥30% liver fat reduction, changes in body weight, body composition, glycemic control, blood pressure, and metabolic and inflammatory markers. 

About Controlled Metabolic Accelerators (CMAs)

Rivus is advancing a new class of oral medicines called Controlled Metabolic Accelerators (CMAs) for obesity and the resulting cardiometabolic diseases. Rivus’ CMAs are designed to induce sustained, fat-selective, muscle-preserving weight loss. These oral small molecule therapeutics are engineered to safely increase resting metabolic rate, which results in increased energy expenditure primarily from fat. Leveraging the natural metabolic process of mitochondrial uncoupling, CMAs increase the resting metabolic rate in a manner that is precision-controlled and imperceptible to the patient. Rivus’ lead CMA HU6 (ANT-channel activator) has demonstrated positive results and a well-tolerated safety profile in across 3 Phase 2 clinical trials in MASH (metabolic dysfunction associated steatohepatitis), MASLD (metabolic dysfunction-associated steatotic liver disease), and HFpEF (heart failure with preserved ejection fraction). In addition, Rivus has a pipeline of novel CMAs in preclinical development for obesity and cardiovascular disease.

About Rivus Pharmaceuticals  

Rivus Pharmaceuticals, Inc. is a clinical-stage biotechnology company advancing novel medicines for obesity and the resulting cardiometabolic diseases. A leader in mitochondrial biology, Rivus is developing a new class of investigational therapies called Controlled Metabolic Accelerators (CMAs), which are oral small molecules designed for sustained, fat-selective, muscle-preserving weight loss. Rivus’ lead candidate HU6 (ANT-channel activator) has demonstrated positive results in three Phase 2 clinical trials across MASH (metabolic dysfunction associated steatohepatitis), MASLD (metabolic dysfunction-associated steatotic liver disease) and HFpEF (heart failure with preserved ejection fraction). In addition to HU6, Rivus is developing a pipeline of preclinical CMAs. Follow Rivus on LinkedIn and X and visit www.rivuspharma.com. 

Contact:

Company Contact: 
Amy Figueroa, CFA
Rivus Pharmaceuticals
afigueroa@rivuspharma.com

Media Contact:
Meredith Mallen 
Real Chemistry  
mmallen@realchemistry.com